Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 172,899 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 172,899 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $37.17, for a total value of $6,426,655.83. Following the completion of the transaction, the insider directly owned 18,630,739 shares in the company, valued at $692,504,568.63. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The shares were sold at an average price of $36.48, for a total value of $5,280,698.88.
• On Thursday, August 20th, Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock. The shares were sold at an average price of $37.30, for a total transaction of $653,458.70.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The stock was sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total transaction of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $36.30 on Friday. The company’s 50 day simple moving average is $34.61 and its 200 day simple moving average is $30.43. The firm has a market capitalization of $26.22 billion, a price-to-earnings ratio of -68.49 and a beta of 1.12. Roivant Sciences Ltd. has a fifty-two week low of $11.60 and a fifty-two week high of $37.97.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. As a group, analysts predict that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Institutional Trading of Roivant Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. Concurrent Investment Advisors LLC increased its position in Roivant Sciences by 336.1% during the second quarter. Concurrent Investment Advisors LLC now owns 190,938 shares of the company’s stock worth $6,757,000 after acquiring an additional 147,151 shares during the period. Wellington Management Group LLP lifted its position in Roivant Sciences by 179.0% during the second quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock worth $95,124,000 after purchasing an additional 1,724,588 shares during the period. Public Employees Retirement System of Ohio bought a new stake in Roivant Sciences during the second quarter worth about $4,936,000. Great Lakes Advisors LLC acquired a new stake in Roivant Sciences during the second quarter worth about $3,815,000. Finally, Handelsbanken Fonder AB increased its holdings in Roivant Sciences by 51.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 177,209 shares of the company’s stock valued at $6,271,000 after buying an additional 60,200 shares during the period. Institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Guggenheim raised their price target on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Leerink Partners set a $42.00 price target on Roivant Sciences in a research report on Thursday, May 21st. Finally, Citigroup upped their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $35.14.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.